<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/237B555C-3B96-48B8-BE18-B91082A9C34F"><gtr:id>237B555C-3B96-48B8-BE18-B91082A9C34F</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>George</gtr:otherNames><gtr:surname>Murray</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700541"><gtr:id>D2348536-5478-4FA3-8AE5-DBD4F606ECC0</gtr:id><gtr:title>The Role of Disordered Ubiquitination in Pre- and Post-natal Growth Restriction</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0700541</gtr:grantReference><gtr:abstractText>There are many children born each year who are small and then grow very slowly in childhood; in some this even continues when they are given treatment with growth hormone. We know how important it is for a child to grow normally so they can get the best from their lives. Often the cause for these children being born small is not known. We have been working on a condition called 3M syndrome, which is a rare cause of being born small and then not growing well after birth. Children with 3M also respond poorly when given growth hormone. We have found that the cause of 3M is a fault in a gene called Cullin 7.

Cullin 7 is found in cells in the body and helps to clear away waste proteins. However we do not know exactly how Cullin 7 affects growth. We intend to work out how Cullin 7 results in 3M children being born small and growing poorly. Knowing the mechanism behind the slow growth in 3M may also help us to find out why other children are born small and to develop new treatments to help more of these children grow better.</gtr:abstractText><gtr:technicalSummary>Low birth weight and being born small for gestational age (SGA) are associated with increased neonatal mortality, small stature in adulthood and cardiovascular mortality in later life. There are over 1300 children each year who qualify for treatment with recombinant human growth hormone (rhGH) due to being SGA with failure of catch up growth. We have focused on 3M syndrome (an autosomal recessive disorder characterised by facial dysmorphism, significant pre- and post-natal growth restriction and normal intelligence) which could be a model disorder to improve our understanding of mechanisms that control growth. Autozygosity mapping studies identified a locus on chromosome 6, and 25 distinct mutations in Cullin 7 (Cul7) in 29 families were found. Cul7 is believed to have a role as a scaffold protein in assembling an E3 ubiquitin ligase complex with Skp1, ROC1 and Fbx29 (1). 3M syndrome may be the result of failure to form this complex and the first demonstration that an abnormality in ubiquitination can cause growth failure.

We have identified that children with 3M syndrome respond very poorly to rhGH and have biochemical features of GH insensitivity. 

This project aims to: 1) Describe the clinical phenotype of a cohort of children with 3M syndrome 2) Identify the prevalence of Cul7 mutations in 3M syndrome and more generally in SGA children, who show a poor response to rhGH treatment 3) Elucidate the underlying mechanism by which Cul7 mutations may impair growth and potentially indicate avenues for novel growth-promoting interventions 4) Assess the effects of knocking down Cul7 and its binding partners in a non-placental vertebrate. 

Clinical, anthropometrical and biochemical data along with samples for DNA will be collected from children with 3M syndrome and SGA children who have a poor response to rhGH. Cul7 will be sequenced in all 3M patients and in our SGA children who demonstrate abnormal waveforms on heteroduplex wave analysis. To identify the mechanism of growth impairment in 3M children studies will be undertaken in normal and Cul7 mutant fibroblasts examining apoptosis and cell growth, basal gene expression, thymidine incorporation, GH receptor trafficking and GH signalling. Xenopus tropicalis will be used to study the effects of knocking down Cul7 using morpholino ologonucleotides in a non-placental vertebrate and to assess gene expression in vivo. 

The opportunity exists to examine the role of ubiquitination in human growth and to identify and areas for potential therapeutic intervention for a common serious growth disorder.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>179171</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Hospital grand Round</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4DD24965-9FAB-4DE5-9409-96F9E442E963</gtr:id><gtr:impact>Presented data on ou research to non-academic audience of staff from the royal manchester children's hospital.

None</gtr:impact><gtr:outcomeId>4CD2CC6A1F5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CMFT R&amp;amp;I Pump Priming</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Manchester University NHS Foundation Trust</gtr:fundingOrg><gtr:id>8338124D-F734-48C9-AAB9-80BD4CBAB9B3</gtr:id><gtr:outcomeId>545b9ba3d30a65.98907548</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Early career grant</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Society for Endocrinology</gtr:fundingOrg><gtr:id>66667E1C-736E-4A41-9EC2-6B5BECB83F79</gtr:id><gtr:outcomeId>TTkZX5qeniJ</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Sequencing of the OBSL1 gene in children with 3-M syndrome.</gtr:description><gtr:id>6E94F598-0C26-42F0-BEEF-CAC8D3D92DF0</gtr:id><gtr:impact>This development allows improved artes of molecular diagnosis for children affected by 3-M syndrome. This can help remove diagnostic confusion.</gtr:impact><gtr:outcomeId>79FA9913907</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>OBSL1 genetic screening</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2007</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Identification of genetic cause for disease now means this can be used as a diagnostic test.</gtr:description><gtr:id>DA9F6DA5-5332-4DBB-B09F-A7D945AFCFFE</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>545ba05c04b174.42754463</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>CCDC8 genetic sequencing</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Human fibroblast cell line derived from patient with 3-M syndrome but no known mutations in CUL7 or OBSL1</gtr:description><gtr:id>9F5FCD26-BDF9-47C0-A84C-2A1CF692E70D</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>5CF4316201F</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>3M syndrome fibroblast cell line CCDC8 mutation</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Human fibroblast cell line with nonsense mutation in cullin 7</gtr:description><gtr:id>4FC4A729-E99D-4038-B176-109D5CDA8030</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>0728B9F7283</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CUL7 -/- human fibroblast cell line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Rabbit polyclonal antibody to OBSL1.</gtr:description><gtr:id>03D7B204-C16A-4243-B474-81034A7A60D2</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>9CB4B42FCE5</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>OBSL1 rabbit polyclonal antibody</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Human fibroblast cell line from patient with 3-M syndrome due to a novel nonsence mutation in Obscurin like-1</gtr:description><gtr:id>7C4FD858-D040-4792-87EB-7A751838D914</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>83C9A646EFC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>OBSl1 -/- cell line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Model of OBSL1 3-M syndrome in Xenopus tropicalis using morpholino oligonucleotides</gtr:description><gtr:id>5ACBBC91-A9B5-4313-8866-2D8C83002D8C</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>576FFC1FBF7</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>OBSL1 knockdown model in Xenopus tropicalis</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7367254D-C850-4531-B601-7B9DBD763AF0</gtr:id><gtr:title>Reduced appetite and body mass index with delayed puberty in a mother and son: association with a rare novel sequence variant in the leptin gene.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fe8e585fd551cf0a52e7b88b36cb57e"><gtr:id>0fe8e585fd551cf0a52e7b88b36cb57e</gtr:id><gtr:otherNames>Murray PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>545b9e4ce4c9c1.70017997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>482795E0-8B01-4C5F-9123-89658D024DA9</gtr:id><gtr:title>Growth hormone, the insulin-like growth factor axis, insulin and cancer risk.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd314e0c318e212e19d2beac42a5d237"><gtr:id>cd314e0c318e212e19d2beac42a5d237</gtr:id><gtr:otherNames>Clayton PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-5029</gtr:issn><gtr:outcomeId>545b9e4d1b5b17.73073520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0834B4E6-D278-449B-9B1B-6B97D6C432BA</gtr:id><gtr:title>Exome sequencing identifies CCDC8 mutations in 3-M syndrome, suggesting that CCDC8 contributes in a pathway with CUL7 and OBSL1 to control human growth.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d8d1e3d4a57ae274d989a9f73f46b6d"><gtr:id>8d8d1e3d4a57ae274d989a9f73f46b6d</gtr:id><gtr:otherNames>Hanson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_24258_28_21737058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>531C6B26-A25D-4E93-8360-5EE3229D2F2D</gtr:id><gtr:title>The primordial growth disorder 3-M syndrome connects ubiquitination to the cytoskeletal adaptor OBSL1.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d8d1e3d4a57ae274d989a9f73f46b6d"><gtr:id>8d8d1e3d4a57ae274d989a9f73f46b6d</gtr:id><gtr:otherNames>Hanson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>FD85468B714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34869B9B-FB70-4710-880D-F4C03C7DAE4B</gtr:id><gtr:title>Metabolites involved in glycolysis and amino acid metabolism are altered in short children born small for gestational age.</gtr:title><gtr:parentPublicationTitle>Pediatric research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fe8e585fd551cf0a52e7b88b36cb57e"><gtr:id>0fe8e585fd551cf0a52e7b88b36cb57e</gtr:id><gtr:otherNames>Murray PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0031-3998</gtr:issn><gtr:outcomeId>58c94e73ed1585.75049102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B49BB8BF-EA75-4B73-A301-6388C8957BC9</gtr:id><gtr:title>Mutations in CUL7, OBSL1 and CCDC8 in 3-M syndrome lead to disordered growth factor signalling.</gtr:title><gtr:parentPublicationTitle>Journal of molecular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d8d1e3d4a57ae274d989a9f73f46b6d"><gtr:id>8d8d1e3d4a57ae274d989a9f73f46b6d</gtr:id><gtr:otherNames>Hanson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0952-5041</gtr:issn><gtr:outcomeId>pm_24258_28_23018678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F6D4B0E-1F51-404D-B0B6-CEE8091AF402</gtr:id><gtr:title>Identifying biological pathways that underlie primordial short stature using network analysis.</gtr:title><gtr:parentPublicationTitle>Journal of molecular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d8d1e3d4a57ae274d989a9f73f46b6d"><gtr:id>8d8d1e3d4a57ae274d989a9f73f46b6d</gtr:id><gtr:otherNames>Hanson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0952-5041</gtr:issn><gtr:outcomeId>pm_540e153e153c9343c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5BB7C37-35AF-4611-B422-0508C2A18094</gtr:id><gtr:title>The genetics of 3-M syndrome: unravelling a potential new regulatory growth pathway.</gtr:title><gtr:parentPublicationTitle>Hormone research in paediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d8d1e3d4a57ae274d989a9f73f46b6d"><gtr:id>8d8d1e3d4a57ae274d989a9f73f46b6d</gtr:id><gtr:otherNames>Hanson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1663-2818</gtr:issn><gtr:outcomeId>545b9e4cb1fb10.39004976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F6EC6B8-5A7F-43C3-9DF7-FA27F5EFB0CF</gtr:id><gtr:title>3-M syndrome: a growth disorder associated with IGF2 silencing.</gtr:title><gtr:parentPublicationTitle>Endocrine connections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fe8e585fd551cf0a52e7b88b36cb57e"><gtr:id>0fe8e585fd551cf0a52e7b88b36cb57e</gtr:id><gtr:otherNames>Murray PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2049-3614</gtr:issn><gtr:outcomeId>pm_24258_28_24148222</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700541</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>